GE HealthCare Technologies Inc. logo

GE HealthCare Technologies Inc.

GEHC

NASDAQHealthcareMedical - Devices

Previous close

$74.82

+$0.76 · +1.03%

Aug 21, 4:00 PM ET

GEHC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

84

Deep Value

Momentum

34

Weakening

Sentiment

63

Bullish

Risk resilience

66

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Peter J. Arduini
Listed since
Dec 15, 2022
Employees
54,000

Market position

Day range

Current $74.82

52-week range

Current $74.82

Open
$74.23
Previous close
$74.06
Volume
2.25M
0.44× average
Average volume
5.13M
Average daily volume
Market cap
33.8B USD
Beta
0.82
Market reference 1
50-day average
$66.6559
+12.25% above average
200-day average
$72.8386
+2.72% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
42.93B USD
P/E (TTM)
21.5×
P/B (TTM)
3.09×
P/S (TTM)
1.67×
EV / EBITDA
11.34×
Earnings yield
5.57%
Free cash flow yield
4.02%
Dividend yield
0.19%

Profitability & efficiency

Gross margin
42.90%
Operating margin
12.70%
Net margin
7.86%
Return on equity
20.08%
Return on assets
5.65%
Return on invested capital
8.84%

Financial health

Debt / equity
0.92×
Current ratio
1.18×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends45%32%18%5%Gross margin, FY2021: 40.80%Gross margin, FY2022: 39.14%Gross margin, FY2023: 40.52%Gross margin, FY2024: 41.71%Gross margin, FY2025: 39.99%Operating margin, FY2021: 15.89%Operating margin, FY2022: 13.75%Operating margin, FY2023: 12.45%Operating margin, FY2024: 13.34%Operating margin, FY2025: 13.39%Net margin, FY2021: 12.78%Net margin, FY2022: 10.45%Net margin, FY2023: 8.02%Net margin, FY2024: 10.13%Net margin, FY2025: 10.10%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 40.80%. Gross margin FY2022 39.14%. Gross margin FY2023 40.52%. Gross margin FY2024 41.71%. Gross margin FY2025 39.99%. Operating margin FY2021 15.89%. Operating margin FY2022 13.75%. Operating margin FY2023 12.45%. Operating margin FY2024 13.34%. Operating margin FY2025 13.39%. Net margin FY2021 12.78%. Net margin FY2022 10.45%. Net margin FY2023 8.02%. Net margin FY2024 10.13%. Net margin FY2025 10.10%.

Income trends

Revenue

20.63B USD+4.84%

Operating income

2.76B USD+5.22%

Net income

2.08B USD+4.57%
Income trends across reported periods22.53B USD14.91B USD7.29B USD−337.7M USDRevenue, FY2021: 17.59B USDRevenue, FY2022: 18.34B USDRevenue, FY2023: 19.55B USDRevenue, FY2024: 19.67B USDRevenue, FY2025: 20.63B USDOperating income, FY2021: 2.8B USDOperating income, FY2022: 2.52B USDOperating income, FY2023: 2.44B USDOperating income, FY2024: 2.63B USDOperating income, FY2025: 2.76B USDNet income, FY2021: 2.25B USDNet income, FY2022: 1.92B USDNet income, FY2023: 1.57B USDNet income, FY2024: 1.99B USDNet income, FY2025: 2.08B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 17.59B USD. Revenue FY2022 18.34B USD. Revenue FY2023 19.55B USD. Revenue FY2024 19.67B USD. Revenue FY2025 20.63B USD. Operating income FY2021 2.8B USD. Operating income FY2022 2.52B USD. Operating income FY2023 2.44B USD. Operating income FY2024 2.63B USD. Operating income FY2025 2.76B USD. Net income FY2021 2.25B USD. Net income FY2022 1.92B USD. Net income FY2023 1.57B USD. Net income FY2024 1.99B USD. Net income FY2025 2.08B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue20.63B USD19.67B USD19.55B USD18.34B USD17.59B USD
Cost of goods sold12.38B USD11.47B USD11.63B USD11.16B USD10.41B USD
Gross profit8.25B USD8.21B USD7.92B USD7.18B USD7.17B USD
Research and development1.26B USD1.31B USD1.21B USD1.03B USD816M USD
Selling, general, and administrative4.23B USD4.27B USD4.28B USD3.63B USD3.56B USD
Operating expenses5.49B USD5.58B USD5.49B USD4.66B USD4.38B USD
Interest income26M USD34M USD
Interest expense450M USD505M USD542M USD86M USD40M USD
Depreciation and amortization578M USD580M USD610M USD633M USD625M USD
Operating income2.76B USD2.63B USD2.44B USD2.52B USD2.8B USD
Net income2.08B USD1.99B USD1.57B USD1.92B USD2.25B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+6.31%
11 comparable reports
Latest EPS result
1.13
Estimate 1.04 · Beat by 8.65%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.511.291.070.86Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 1.45, estimate 1.26, surprise +15.08%, Beat. Q2 2025, reported Apr 30, 2025: actual 1.01, estimate 0.914, surprise +10.50%, Beat. Q3 2025, reported Jul 30, 2025: actual 1.06, estimate 0.918, surprise +15.47%, Beat. Q4 2025, reported Oct 29, 2025: actual 1.07, estimate 1.05, surprise +1.90%, Beat. Q1 2026, reported Feb 4, 2026: actual 1.44, estimate 1.4, surprise +2.86%, Beat. Q2 2026, reported Apr 29, 2026: actual 0.99, estimate 1.04, surprise -4.81%, Miss. Q3 2026, reported Jul 29, 2026: actual 1.13, estimate 1.04, surprise +8.65%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 1.21, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.93B5.43B4.93B4.43BQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 5.32B USD, estimate 5.33B USD, surprise -0.23%, Miss. Q2 2025, reported Apr 30, 2025: actual 4.78B USD, estimate 4.66B USD, surprise +2.52%, Beat. Q3 2025, reported Jul 30, 2025: actual 5.01B USD, estimate 4.97B USD, surprise +0.66%, Beat. Q4 2025, reported Oct 29, 2025: actual 5.14B USD, estimate 5.09B USD, surprise +1.10%, Beat. Q1 2026, reported Feb 4, 2026: actual 5.7B USD, estimate 5.61B USD, surprise +1.51%, Beat. Q2 2026, reported Apr 29, 2026: actual 5.13B USD, estimate 5.04B USD, surprise +1.76%, Beat. Q3 2026, reported Jul 29, 2026: actual 5.3B USD, estimate 5.26B USD, surprise +0.59%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 5.35B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

18 ratings
Strong buy00%
Buy1056%
Hold844%
Sell00%
Strong sell00%

GEHC peers

ETFs holding GEHC

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research GEHC

research.disclaimer